"Pharmaceutical Headlines" two multinational pharmaceutical companies announced major personnel changes.

(2020/09/27) Gilead's $21 billion acquisition of Immunomedics is not worth it; (Click on the title for the original article) Is Gilead's $21 billion acquisition of Immunomedics worthless? In mid-September, Gilead announced a deal to buy Immunomedics, the developer of antibody-linked drugs (ADC), for $21bn.
the acquisition brought Trodelvy, a commercial product to Gilead.
, the first Trap-2 targeted ADC drug, was approved by the FDA in April to treat adult patients with metastasis triple-negative breast cancer (mTNBC) who have received at least two treatments for metastasis.
: The ADC drug market will reach $9.93 billion by 2025.
"New Kangjie" one break three: Drug Mingkangde's capitalization road as China's CRO industry leader enterprises, Pharmaceutical Mingkangde has long been considered to be the closest to the international innovative pharmaceutical giant's company, has entered the global CRO company's top 10 list.
, in addition to the achievements of business development, pharmaceutical Mingkangde's capital operation is also extremely successful, is China's capital market benchmark enterprises.
this article will detail the path of capitalization of drug Mingkangde and analyze its impact.
: The proper operation of capital markets is crucial to the development of enterprises.
Medical Representative, Mercadon, GSK announce personnel changes! On September 25th, It was announced that Wang Zhen, the executive director of Merca East China's current human resources business partner, had decided to leave the company to seek external development opportunities.
, another multinational pharmaceutical company, also had personnel changes today, with Lin Ziming, head of the South China operations of the respiratory division, deciding to leave GSK for personal reasons, the last working day being October 31.
headlines: catch up with the last wave of departures in September.
"Mi Net" East Sunshine Medicine, Huahai... 60 new drugs approved clinically! Between September 12th and September 25th, the listing applications of five new drugs (6 acceptance numbers) were updated with the status of the review and approval.
Reding Pharmaceuticals' toluene sulfonate Nirapali capsules, Roche's Beva bead monoantigen injections were approved for new adaptations, Cinda Bio's Lytoxi monoantigen injections, Pfizer's chlorobenzene softgels, merck Sante's chlorate diazepam tablet registration status changed to "in-approval".
headline bacteria: domestic 1 class of new drugs outbreak.
.